AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Fletcher shares drop 13% after Ebit guidance cut
Markets

Fletcher shares drop 13% after Ebit guidance cut

The company cited 'tough market conditions' as the main reason for softer sales.

Rakon flags mystery $400m bidder's concerns
Markets

Rakon flags mystery $400m bidder's concerns

Tech company has confidential deal in the works to sell business but has warned of snags.

Sales growth gap between Noel Leeming and JB Hi-Fi widens
Retail

Sales growth gap between Noel Leeming and JB Hi-Fi widens

JB Hi-Fi's third-quarter New Zealand sales rose 16.8% compared with last year.

NZ sharemarket slips back into negative territory
Markets Market close

NZ sharemarket slips back into negative territory

The S&P/NZX 50 Index closed at 11,755.17, up 8.58 points or 0.07%.

Graham Skellern 10 May 2024